← Leaderboards
Hassane M Zarour
University Of Pittsburgh At Pittsburgh
$16,372,397
Attributed
$18,199,615
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,621,860 · 16
By mechanism
P50$14,181,883 · 7
R01$12,685,960 · 6
U01$1,735,364 · 1
M01$18,653 · 2
Top collaborators
- John Munn Kirkwood7 shared
- Diwakar Davar5 shared
- Giorgio Trinchieri2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- John Munn Kirkwood$15,450,309
- Louis D Falo$30,012,458
- Joanne L. Flynn$43,717,509
- Alicia R Mathers$4,373,803
- Zhiliang Wang$143,080
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaResponseTumorResistanceCd8b1 GeneT-LymphocyteTumor AntigensClinical TrialsBaseImmunologicsCombinatorialCellsProgrammed Cell Death Protein 1Immune ResponseMelanoma CellMalignant NeoplasmsMonoclonal AntibodiesResearch Project GrantsCell DeathExhaustImmuneCd8-Positive T-LymphocytesT Cell ResponseTumor Microenvironment
Grant awards (60)
Melanoma and Skin Cancer Program SPORE$2,217,934
P50 · FY2025 · CA · contact PI
Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors$632,135
U01 · FY2025 · CA · contact PI
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$481,846
R01 · FY2025 · CA · contact PI
Administrative Core$345,373
P50 · FY2025 · CA · contact PI
Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)$50,414
P50 · FY2025 · CA · contact PI
Melanoma and Skin Cancer Program SPORE$2,121,665
P50 · FY2024 · CA · contact PI
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$457,754
R01 · FY2024 · CA · contact PI
Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors$438,800
U01 · FY2024 · CA · contact PI
Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)$381,600
P50 · FY2024 · CA · contact PI
Administrative Core$250,959
P50 · FY2024 · CA · contact PI
Melanoma and Skin Cancer Program SPORE$1,974,834
P50 · FY2023 · CA · contact PI
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$534,470
R01 · FY2023 · CA · contact PI
Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors$427,661
U01 · FY2023 · CA · contact PI
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma$369,675
P50 · FY2023 · CA · contact PI
Administrative Core$243,115
P50 · FY2023 · CA · contact PI
Melanoma and Skin Cancer Program SPORE$2,070,180
P50 · FY2022 · CA · contact PI
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$531,996
R01 · FY2022 · CA · contact PI
Fecal Microbiota Transplant and PD-1 blockade in Melanoma$505,070
R01 · FY2022 · CA · contact PI
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma$378,023
P50 · FY2022 · CA · contact PI
Targeting TIGIT and PD-1 in Melanoma$350,834
R01 · FY2022 · CA · contact PI
Administrative Core$241,935
P50 · FY2022 · CA · contact PI
Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors$236,768
U01 · FY2022 · CA · contact PI
Melanoma and Skin Cancer Program SPORE$2,037,632
P50 · FY2021 · CA · contact PI
Fecal Microbiota Transplant and PD-1 blockade in Melanoma$573,831
R01 · FY2021 · CA · contact PI
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma$551,927
R01 · FY2021 · CA · contact PI
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma$363,864
P50 · FY2021 · CA · contact PI
Targeting TIGIT and PD-1 in Melanoma$357,994
R01 · FY2021 · CA · contact PI
Administrative Core$239,291
P50 · FY2021 · CA · contact PI
Fecal Microbiota Transplant and PD-1 blockade in Melanoma$498,492
R01 · FY2020 · CA · contact PI
Targeting TIGIT and PD-1 in Melanoma$357,994
R01 · FY2020 · CA · contact PI
Fecal Microbiota Transplant and PD-1 blockade in Melanoma$465,896
R01 · FY2019 · CA · contact PI
Targeting TIGIT and PD-1 in Melanoma$347,253
R01 · FY2019 · CA · contact PI
Fecal Microbiota Transplant and PD-1 blockade in Melanoma$481,349
R01 · FY2018 · CA · contact PI
Targeting TIGIT and PD-1 in Melanoma$357,804
R01 · FY2018 · CA · contact PI
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma$355,405
P50 · FY2018 · CA · contact PI
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma$280,797
P50 · FY2017 · CA · contact PI
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma$259,187
P50 · FY2016 · CA · contact PI
Reversing melanoma-induced T cell dysfunction$314,363
R01 · FY2015 · CA · contact PI
Reversing melanoma-induced T cell dysfunction$304,932
R01 · FY2014 · CA · contact PI
Reversing melanoma-induced T cell dysfunction$295,501
R01 · FY2013 · CA · contact PI
Optimization of Melanoma Vaccines with T-Helper Epitopes$247,310
R01 · FY2013 · CA · contact PI
Reversing melanoma-induced T cell dysfunction$314,363
R01 · FY2012 · CA · contact PI
Optimization of Melanoma Vaccines with T-Helper Epitopes$263,096
R01 · FY2012 · CA · contact PI
Reversing melanoma-induced T cell dysfunction$314,363
R01 · FY2011 · CA · contact PI
Optimization of Melanoma Vaccines with T-Helper Epitopes$263,096
R01 · FY2011 · CA · contact PI
Optimization of Melanoma Vaccines with T-Helper Epitopes$271,233
R01 · FY2010 · CA · contact PI
Melanoma Vaccines with Peptides, Protein and Adjuvant$304,428
R01 · FY2009 · CA · contact PI
Optimization of Melanoma Vaccines with T-Helper Epitopes$271,233
R01 · FY2009 · CA · contact PI
Melanoma Vaccines with Peptides, Protein and Adjuvant$324,109
R01 · FY2008 · CA · contact PI
Melanoma Vaccines with Peptides, Protein and Adjuvant$322,561
R01 · FY2007 · CA · contact PI
Optimization of Melanoma Vaccine with T Helper Epitope$74,214
R01 · FY2007 · CA · contact PI
Melanoma Vaccines with Peptides, Protein and Adjuvant$314,446
R01 · FY2006 · CA · contact PI
Optimization of Melanoma Vaccine with T Helper Epitope$258,118
R01 · FY2006 · CA · contact PI
Melanoma Vaccines with Peptides, Protein and Adjuvant$314,094
R01 · FY2005 · CA
Optimization of Melanoma Vaccine with T Helper Epitope$264,330
R01 · FY2005 · CA
PILOT IMMUN W/CPG 7909 OR MULTI-EPITOPE IMMUNOGEN NYESO-1$18,320
M01 · FY2005 · RR
PROMUNE W/WO CHEMO TRTMT STAGE III B/C/IV MELANOMA$333
M01 · FY2005 · RR
Optimization of Melanoma Vaccine with T Helper Epitope$264,330
R01 · FY2004 · CA
Optimization of Melanoma Vaccine with T Helper Epitope$265,220
R01 · FY2003 · CA
Optimization of Melanoma Vaccine with T Helper Epitope$266,110
R01 · FY2002 · CA